{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:34Z","timestamp":1779951754552,"version":"3.53.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA CAR-T) has significantly improved outcomes in relapsed\/refractory multiple myeloma (R\/RMM), yet its spectrum of immune-related adverse events continues to be defined. Among these, cutaneous toxicities are not unusual, but frequently receive insufficient attention. Delayed-onset cutaneous reactions, in particular, may be underreported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a patient with R\/RMM who achieved stringent complete response (sCR) following BCMA CAR-T therapy and developed delayed-onset cutaneous lesions on day 50 post-infusion. Histopathology revealed dense dermal neutrophilic infiltration, consistent with Sweet\u2019s syndrome. However, the patient lacked typical clinical features such as fever, arthralgia, or peripheral neutrophilia, prompting a diagnosis of \u2018Sweet-like syndrome\u2019 associated with CAR-T therapy. The lesions resolved spontaneously without systemic glucocorticoid therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, virtually no cases of Sweet\u2019s syndrome or Sweet\u2212like syndrome have been reported previously after BCMA CAR\u2212T therapy, broadening the recognized spectrum of CAR\u2212T\u2212related cutaneous adverse events and underscoring the importance of early biopsy for atypical, delayed\u2212onset rashes\u2014rather than empiric systemic corticosteroid treatment\u2014to guide appropriate management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1844119","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:17:25Z","timestamp":1779949045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Xianfeng","family":"Ouyang","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiujiang First People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiujiang First People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiujiang First People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linchun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2025.07.005","article-title":"Major adverse events with chimeric antigen receptor T-cell therapy: Presentation, diagnosis, and resuscitation","volume":"87","author":"Dimitrov","year":"2026","journal-title":"Ann Emerg Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1035.e1","DOI":"10.1016\/j.jtct.2024.06.024","article-title":"Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system","volume":"30","author":"Storgard","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081x(93)90112-p","article-title":"Sweet\u2019s syndrome and cancer","volume":"11","author":"Cohen","year":"1993","journal-title":"Clin Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2141.2005.05636.x","article-title":"Bortezomib-induced sweet syndrome","volume":"131","author":"Knoops","year":"2005","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.011","article-title":"Neutrophilic dermatosis complicating lenalidomide therapy","volume":"61","author":"Thieu","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2033219","article-title":"Acute febrile neutrophilic dermatosis","volume":"385","author":"Ayyash","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1964.tb14541.x","article-title":"An acute febrile neutrophilic dermatosis","volume":"76","author":"Sweet","year":"1964","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(94)70215-2","article-title":"Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis)","volume":"31","author":"von den Driesch","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12172","article-title":"Sweet-like syndrome induced by bortezomib","volume":"11","author":"Kolb-M\u00e4urer","year":"2013","journal-title":"J Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"B13","article-title":"Sweet-like syndrome in a patient with acute myeloid leukaemia","volume":"37","author":"Norhaya","year":"1996","journal-title":"Singapore Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01996.x","article-title":"Cutaneous manifestations of granulocyte colony-stimulating factor","volume":"31","author":"White","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.0303-6987.2002.029.x","article-title":"Sweet syndrome in multiple myeloma: a series of six cases","volume":"30","author":"Bayer-Garner","year":"2003","journal-title":"J Cutan Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.25270\/wnds\/24111","article-title":"Pyoderma gangrenosum secondary to chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma","volume":"37","author":"Mager","year":"2025","journal-title":"Wounds Compend Clin Res Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:17:26Z","timestamp":1779949046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1844119"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1844119","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1844119"}}